Rituximab Trumps Natalizumab in MS Relapse Rituximab Trumps Natalizumab in MS Relapse

Although rituximab was consistently linked to better relapse outcomes vs natalizumab in new research, outcomes did not differ between dimethyl fumarate and fingolimod.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news